```
1
       Title: Geographic Differences in Early Kidney Transplant Access in Four US Regions
 2
       Authors: Jade Buford, MPH<sup>1</sup>, Mengyu Di, MSPH<sup>1</sup>, Jessica L. Harding, PhD<sup>2</sup>, Kelsey Drewry, PhD<sup>1,3</sup>,
 3
       Catherine Kelty, PhD<sup>3</sup>, Adam Wilk, PhD<sup>1,3</sup>, Anne Huml, MD<sup>4</sup>, Ana P. Rossi, MD, MPH<sup>5</sup>, Sumit Mohan,
 4
       MD<sup>6</sup>, Bruce E. Gelb<sup>7</sup>, Goni Katz-Greenberg, MD<sup>8</sup>, Bhavna Chopra, MD<sup>9</sup>, Daniel Glicklich, MD, FRCP<sup>10</sup>,
 5
       Prince Mohan Anand, MD<sup>11</sup>, Matthew Handmacher, MD<sup>12, 13</sup>, Laura Mulloy, DO<sup>14</sup>, Wasim A. Dar, MD,
 6
       PhD<sup>15</sup>, Amber Reeves-Daniel, DO<sup>16</sup>, Enver Akalin, MD, FAST, FASN<sup>17</sup>, Kenneth J. McPartland, MD<sup>18</sup>,
 7
       Stephen O. Pastan, MD<sup>2</sup>, Rachel E. Patzer, PhD, MPH<sup>1,3</sup>
 8
 9
10
       Affiliation:
       <sup>1</sup>Regenstrief Institute, Indianapolis, IN
11
12
       <sup>2</sup>Emory University, Atlanta, GA
13
       <sup>3</sup>Indiana University, Indianapolis, IN
       <sup>4</sup>Cleveland Clinic, Cleveland, OH
14
       <sup>5</sup>Piedmont Transplant Institute, Atlanta, GA
15
       <sup>6</sup>Columbia University, New York, NY
16
17
       <sup>7</sup>NYU Langone Health, New York, NY
18
       <sup>8</sup>Duke University, Durham, NC
       <sup>9</sup>Beth Israel Deaconess Medical Center, Boston, MA
19
20
       <sup>10</sup>Westchester Medical Center, New York Medical College, Valhalla, NY
       <sup>11</sup>Medical University of South Carolina, Lancaster, SC
21
       <sup>12</sup>Erie County Medical Center, Buffalo, NY
22
       <sup>13</sup>University at Buffalo Jacobs School of Medicine, Buffalo, NY
23
       <sup>14</sup>Medical College of Georgia at Augusta University, Augusta, GA
24
       <sup>15</sup>Hartford Hospital Comprehensive Transplant Center, Hartford, CT
25
       <sup>16</sup>Wake Forest Medical Center, Atlanta, GA
26
       <sup>17</sup>Montefiore Medical Center, Bronx, NY
27
       <sup>18</sup>Baystate Medical Center, Kidney Transplant Program, Springfield, MA
28
29
30
31
       Corresponding Author:
32
       Rachel E. Patzer, PhD, MPH
33
       Professor, Indiana University School of Medicine
       1101 West 10th Street
34
       Indianapolis, IN 46202
35
36
       Telephone number: 317-274-9324
37
       Email address: rapatzer@iu.edu
38
39
40
       Target Journal: JAMA
41
42
       Word Count:
       Title: 75/100 characters (with spaces)
43
44
       Key Points: 100/100 words
45
       Abstract: 342/350
46
       Text: 3000/3000 words
47
       Tables/Figures: 3 tables and 2 figures/≤5 tables and/or figures
48
49
50
       Keywords:
51
```

KEY POINTS Question: Is there geographic variation in dialysis facility-level rates of pre-transplant access (i.e., starting the medical evaluation within 6 months of referral) and being added to the waitlist for a kidney transplant across four US regions? Findings: In this retrospective cohort study of 62,467 adults referred for kidney transplantation, regionspecific median within-facility evaluation start ranged from 33.3% in the Ohio River Valley to 66.7% in New York, while for waitlisting ranged from 31.9% in the Southeast to 50% in the other regions. Meaning: Geographic variation in pre-transplant access underscores the need for federal efforts to address inequities in access to pre-transplant care processes.

ABSTRACT 95 96 97 Importance: Research has highlighted variability in access to kidney transplant evaluation and 98 waitlisting in the Southeast, yet little is known about variation in access across other U.S. regions, 99 hindering broader efforts to improve access. 100 **Objective:** Describe geographic variation in dialysis facility-level rates of evaluation start and waitlisting 101 across four U.S. regions. 102 **Design:** Retrospective cohort study of adults referred for transplantation and initiating transplant evaluation captured within the Early Steps to Transplant Access Registry (1/1/2015 to 12/31/2023), 103 104 linked with the US Renal Data System, and waitlisting data from the Scientific Registry of Transplant 105 Recipients with follow-up through 3/02/2024. 106 **Setting:** U.S. dialysis facilities 107 Participants: 62,467 adults (ages 18-79) referred from 2,471 dialysis facilities; 27,171 who started the 108 evaluation from 2,188 referring dialysis facilities. 109 **Exposures:** Dialyzing in New England, New York, Southeast, and Ohio River Valley. Main Outcome(s) and Measure(s): Dialysis facility-level rates of evaluation (within six months of 110 111 referral) and waitlisting (within one year of evaluation start). **Results:** Among 62,467 patients within 2,471 dialysis facilities, the percentage of patients who started the 112 transplant evaluation within six months varied from 0% to 100%; the median within-facility evaluation 113 114 start rate was 50% (interquartile range (IQR): 33.3%-64.3%) across all four regions, ranging from 33.3% (18.2%-50%) in the Ohio River Valley to 66.7% (50%-76.7%) in New York. Waitlisting rates within one 115 116 year of evaluation varied from 0% to 100% across 2,188 facilities; the median within-facility percentage of patients waitlisted within one year of evaluation start was 41.2% (26.0%-60%), with the lowest 117 118 percentage in the Southeast (31.9% (20%-43.8%). Facilities in the lowest tertile of evaluation start

(<39.13%) were more likely to treat patients living in high-poverty neighborhoods (36.8% vs 29.2%), had

120	a higher patient-to-social worker ratio (49.2 vs. 46.26), and were more likely for profit (82.4% vs 73.5%)
121	than the highest tertile (>58.33%). These characteristics varied by region. After accounting for patient
122	case-mix, facility-level clustering explained 12.2% (95% CI: 10.5-13.5) of the variation in evaluation
123	start and 8.2% (6.7–9.2) of the variation in waitlisting across dialysis facilities.
124	Conclusions and Relevance: There is substantial variation in early transplant access among U.S. dialysis
125	facilities, which differs by geographic region.
126	
127	
128	
129	
130	
131	
132	
133	
134	
135	
136	
137	
138	
139	
140	
141	
142	
143	
144	
145	
146 147	
147	
1 1 0	

INTRODUCTION

Kidney transplantation is the preferred treatment option for most individuals with end-stage kidney disease (ESKD), offering increased life expectancy, improved quality of life, and lower costs relative to in-center dialysis. ¹⁻³ However, access to transplantation is limited and variable, with long-standing racial, socioeconomic, and geographic disparities at all steps of the transplant process. ⁴⁻¹³ Drivers of these disparities are multi-faceted, and barriers exist at the patient, provider, neighborhood, and health system levels. ¹³⁻¹⁵ Although barriers to transplant post-waitlisting are well-documented, less is known about access to pre-waitlisting care steps (e.g., referral, evaluation start) owing to a lack of national surveillance data on these critical steps.

What is known about pre-waitlisting access largely comes from studies using the Early Steps to Transplant Access Registry (E-STAR), which has collected referral and evaluation start data from all transplant centers in the Southeast US for over a decade. Across 690 Southeastern dialysis facilities, we have shown substantial variation in referral and evaluation start rates, both ranging from 0% to 100% across dialysis facilities, with a median one-year referral rate of 33.7% and only 16.1% of patients started the medical evaluation process within six months of referral during 2012-2018. Geographic variations in time to waitlisting and rates of deceased donor kidney transplant have also been found in national analyses across the 57 donor service areas. The started transplant have also been found in national

Given the known geographic variability in transplant access and the critical role that dialysis facilities play in pre-transplant care — including education and referral for transplant evaluation — understanding variability in access and factors associated with high or low rates of access both within and between geographic regions¹⁹ is essential to inform and standardize policies. In 2019, E-STAR expanded to include 10 additional states in the Northeast and Midwest, enabling the examination of geographic variation in pre-transplant care steps. Therefore, using this new data, we extend our prior research to describe regional variation in dialysis facility-level rates of evaluation start and waitlisting. Results may inform the Health Resources and Services Administration's (HRSA) recent national pre-waitlisting data collection efforts and support new federal initiatives — such as the implementation of the bipartisan-

supported 2023 Securing the U.S. Organ Procurement and Transplantation Network (OPTN) Act,²⁰ calling for substantial increases in access to transplantation. Findings may also aid in implementing and evaluating the new Increasing Organ Transplant Access Model (IOTA),²¹ a performance-based incentive model aimed at improving transplant access.

METHODS

Data Sources

Patient-level referral and evaluation data (n=321,871 referral records representing ~217,000 patients) were collected from transplant referral forms and electronic medical records at 36 of the 48 transplant centers in New England (Network 1: CT, MA, ME, NH, RI, VT – 10/14 centers, 71%), New York (Network 2: NY – 10/13 centers, 77%), the Southeast (ESRD Network 6: GA, NC, SC – 11/11 centers, 100%), and the Ohio River Valley (Network 9: IN, KY, OH – 5/10 centers, 50%) from 1/1/2012, through 12/31/2023. Transplant center data availability varied due to openings, closures, and other administrative reasons (eTables 1 and 2). Detailed methods of the data collection process are available elsewhere.⁵

Patient-level characteristics reported by clinicians on the CMS Medical Evidence Form (2728 form) within 45 days of dialysis initiation were obtained via linkage to the United States Renal Data System (USRDS), a registry of all individuals initiating kidney replacement therapy (dialysis or transplant) in the US. Data on all adults waitlisted for kidney transplantation were obtained via the Scientific Registry of Transplant Recipients and linked to USRDS data via a unique patient identifier. Facility-level characteristics were obtained from the annual USRDS facility survey. Characteristics of patients' residential neighborhood via 5-digit ZIP code tabulation area linkage were obtained from 2014-2018 American Community Survey data

The Institutional Review Boards at Emory (IRB00113572) and Indiana (IRB #18998)
Universities approved this study.

Study population

The two study cohorts included all adults (ages 18-79 years at dialysis) who were referred (Cohort 1) and/or started the evaluation (Cohort 2) at one of 36 E-STAR-participating transplant centers from 1/1/2015 to 12/31/2023 (3/2/2023 for evaluation). Patients were assigned to the first facility where they received dialysis services. Preemptively (i.e., before dialysis initiation) referred (n=10,060), evaluated (n=141), or waitlisted (n=154,456) individuals, as well as individuals whose first treatment modality did not involve dialysis (i.e., died, had unknown dialysis status, recovered kidney function, received a preemptive transplant, were lost to follow-up, or nursing home hemodialysis, n=260,447) and those with less than six months of follow-up (n=631) were excluded. The final analytic samples comprised 62,467 adults referred (Cohort 1) and 27,171 who started the evaluation (Cohort 2; **Figure 1**).

Study Outcomes

The primary outcome was evaluation start within six months of first referral. Here, we broadly define evaluation start as the date when a patient initiated a required component of the transplant evaluation process (a more complete definition is in the eAppendix and **Table S3**). Individuals were followed from date of first referral until evaluation date or 12/31/2023 (end of follow-up in E-STAR). The secondary outcome was waitlisting within one year of evaluation start, defined using date of first placement on the kidney waitlist. We examined dialysis facility-level variation by grouping patients by dialysis facility and calculating the percentages of each of our outcomes. Individuals were followed from evaluation start date until waitlisting or 3/02/2024 (end of follow-up in SRTR). Detailed information on data availability for follow-up for our outcomes by center can be found in the **Supplement**.

Covariates

Patient characteristics included race and ethnicity (non-Hispanic White, Black, Hispanic White, other race or ethnicity: American Indian/Alaska Native, Native Hawaiian/Pacific Islander, Multiracial, and Pacific Islander, Middle Eastern Subcategory, and Indian Subcategory), age, sex, cause of ESKD, and comorbidities (see **Table 1**). Patient-level proxies for socioeconomic status included receipt of pre-ESKD

nephrology care (yes, no) and primary source of health insurance at dialysis start (Medicare, Medicaid, employer group coverage, other coverage, no coverage). A hierarchy of employer group coverage, Medicare, Medicaid, other, and no coverage was used to assign a single primary source of coverage for individuals with multiple sources of health insurance listed. Measures of neighborhood socioeconomic status using the patients' residential 5-digit ZIP code included the proportion of black residents, residents aged ≥25 years without a high school degree or equivalent, and neighborhood poverty, defined as ≥20% or <20% of households living below the poverty level. Dialysis facility characteristics included the annual number of patients per facility, the patient-to-social worker ratio, profit status (for-profit, non-profit), and hospital-based versus freestanding facility.

Statistical Analyses

Patient and dialysis-facility characteristics at dialysis start were summarized overall and by region (New York, New England, Southeast, Ohio River Valley) using analysis of variance (ANOVA) and chi-squared tests for continuous and categorical variables, respectively. Waterfall plots illustrate the distribution of these percentages of each of our outcomes at the facility-level by region. An intraclass correlation coefficient estimated the proportion of total variance in the outcome attributable to facility-level clustering. Facilities were stratified into tertiles based on these percentages, and facility and aggregated patient characteristics were compared to assess whether they differed by high, middle, and low tertiles overall, and whether these patterns varied by region. To further examine regional differences, we used cumulative incidence functions to estimate the probabilities of each outcome by region, treating death as a competing risk and censoring for loss to follow-up or study end. Unadjusted and adjusted ²²) and time to each event. We calculated crude and adjusted sub-distribution hazard ratios with 95% confidence intervals (CI) for each outcome, accounting for death as a competing risk, and including a random intercept for facility-level heterogeneity and interaction terms by region.

RESULTS

Baseline Characteristics

Among the 62,467 referred individuals in E-STAR, the mean age at dialysis start was 53 years (SD: 14; **Table 1**). In the Southeast, 64.9% of referred patients were Black, while in New England (53.9%) and the Ohio River Valley (55.9%) the majority were non-Hispanic white. New York had a greater proportion of individuals identified as Hispanic white and other racial and ethnic groups compared to other regions. Among the 2,471 referring dialysis facilities, 83.5% were for-profit, 92.1% were freestanding, and the mean patient-to-social worker ratio was 64.3. Other baseline characteristics were largely similar across regions (**Table 1**).

Dialysis-Facility-Level Variation in Rates of Evaluation Start and Waitlisting

Among 2,471 dialysis facilities, the median percentage of patients starting the evaluation within six months was 50.0% (interquartile range (IQR): 33.3%-64.3%). The median within-facility proportions of evaluation start within six months of referral were lowest in the Ohio River Valley at 33.3% (18.2%-50.0%) and greatest in New York, at 66.7% (50.0%-76.7%). The median proportion of patients starting the evaluation within 6 months of referral was 52.7% (39.1%-66.7%) in New England and 50% (38.5%-60.0%) in the Southeast. For waitlisting within one year of evaluation start among 2,188 facilities, the median percentage was 50.0% (38.9%-72.4%), 50.0% (33.3%-75%), 50.0% (33.3%-70.0%), and 31.9% (20%-43.8%) in New England, New York, the Ohio River Valley, and the Southeast, respectively. Across all regions, both outcomes varied significantly across the dialysis facilities, ranging from 0% to 100% (**Figure 2**). After accounting for patient mix, facility-level clustering explained 12.2% (95% CI: 10.5-13.5) of the variation in evaluation start and 8.2% (95% CI: 6.7-9.2) of the variation in waitlisting.

Characteristics of facilities in the highest (i.e. highest evaluation rates) versus lowest tertile of evaluation rates varied. For example, facilities in the lowest tertile had a higher patient-to-social worker ratio (49.2 [95% CI: 47.13-51.28) vs. 46.26 [43.71-48.82]), a higher proportion of adults aged 60–80, fewer Black adults (40.0% [95% CI: 37.7–42.3] vs. 45.0% [42.8–47.2]), a greater proportion of adults

with diabetes as the attributed cause of ESKD (42.0% [40.3–43.6] vs. 36.4% [34.9–38.0]), and higher prevalence of most comorbidities examined. The lowest tertile had a higher proportion of adults with Medicare or no health insurance coverage at dialysis start, while employer-sponsored insurance was more common in the highest tertile. The lowest-tertile also facilities treating adults residing in neighborhoods with fewer Black residents (21.0% [19.7–22.3] vs 25.9% [24.5–27.3]), higher poverty (36.8% [34.6–39.1] vs 29.2% [27.2–31.1]), and had a greater mean patient volume and a higher proportion of for-profit dialysis centers (82.4% vs 73.5%; **Table 2**). Characteristics of facilities in the lowest tertile of waitlisting rates were similar to those with low evaluation start (**Table 3**).

Differences between facilities with low or high tertiles of evaluation and waitlisting rates were observed across regions (results not shown). For example, in New England and the Ohio River Valley, the lowest tertile facilities had a higher proportion of older adults, while no age differences were observed in the Southeast. Facilities in the lowest tertile for evaluation start in New York and the Southeast had a lower proportion of patients with Medicaid or no health insurance, while in New England and the Ohio River Valley, no significant differences were observed across these insurance groups. For-profit dialysis centers were more common in the lowest tertile in New England, New York, and the Ohio River Valley, but in the highest tertile in the Southeast. The lowest tertile of waitlisting rates in New England, New York, and the Ohio River Valley had higher mean patient volume and patient-to-social worker ratios, whereas these characteristics were greater in the highest tertile in the Southeast.

Results examining the cumulative incidence of our outcomes (eTable 4; eFigure 1 and 2), along with unadjusted and multivariable-adjusted competing risk analyses comparing access to each outcome for individuals in the Southeast versus the other three regions, yielded findings consistent with the crude rates (eTable 5).

DISCUSSION

This is the first study to assess variation in dialysis-facility rates of evaluation start and waitlisting across four regions of the US. We show substantial variation across regions, with within-facility rates in

these steps ranging from 0% to 100% across dialysis facilities. The within-facility median percentage of referred patients starting the evaluation within six months was 50%, ranging widely from 33.3% in the Ohio River Valley to 66.7% in New York. Median within-facility rates of waitlisting within 1 year of evaluation start were relatively consistent but lowest in the Southeast, a region with historically low rates of timely waitlisting. In Importantly, characteristics of facilities with high and low evaluation start and waitlisting rates differed by region, suggesting that region-specific strategies may be needed. For example, in New England, New York, and the Ohio River Valley, for-profit dialysis centers were more common in the lowest tertile of evaluation start but more common in the highest tertile in the Ohio River Valley. These results suggest that barriers in access to evaluation vary across geographic regions, emphasizing the importance of federal, regional, and local interventions to improve kidney transplant access.

Our findings highlight that, at the median, half of referred individuals start the evaluation within six months of referral in the Southeast and New England. In contrast, we report for the first time that only one-third of individuals start the evaluation within six months of referral in the Ohio River Valley, while two-thirds start the evaluation in New York. Regional differences in evaluation start may be explained by greater population density and concentration of large volume transplant centers in the Northeast compared to the Southeast and Ohio River Valley. Transportation barriers may further contribute to these differences. A review by Harding *et al.* reported several non-medical barriers to pre-waitlisting steps, including distance to the transplant center, travel time, and transportation access. ¹³ Lack of transportation has been linked with missed appointments and delayed healthcare access, ²³ and is more commonly faced among individuals residing in non-urban areas compared to those in urban areas, ²⁴ such as New York City, who have greater access to transportation resources to attend the evaluation appointment. ²⁵ Some geographic variation can likely be explained by differences in patient experiences of medical mistrust, racism, and discrimination — previously linked to lower access to evaluation start ²⁶ — along with other difficult-to-measure influences on access. Differences in the racial composition of patients across the four regions in the present study can influence how these barriers manifest.

Numerous dialysis facility-level factors may prevent referred patients from starting the evaluation in a timely manner. One of the most common contributors to patient drop-off after referral is a lack of understanding of the evaluation process.²⁷ A recent study of individuals with chronic kidney disease across these same 4 regions highlighted variability in education practices about transplantation for patients between health systems as a major barrier to the pursuit of a kidney transplant.²⁸ In addition to variability in patient education and knowledge, transplant-center-specific policies and practices related to the prioritization of referrals²⁹ and referral closure likely have a large role in evaluation start and dialysis facility practices post-referral.

Aligning with prior studies^{5,16} we show similar patient- and facility-level factors associated with lower and higher rates of evaluation start and waitlisting within dialysis facilities. However, our findings also highlight regional differences. We found that facilities in the highest tertile of evaluation start and waitlisting performance had a higher proportion of patients with employer-sponsored insurance across all regions, while facilities within the lowest tertiles had a greater proportion of patients residing in areas of high-poverty neighborhoods in New England, New York, and the Southeast. These results highlight the complex relationship between socioeconomic factors and healthcare access, where residing in high-poverty neighborhoods can limit individuals' progression. Areas of high concentrations of poverty, such as in New York and the Southeast, also often have greater challenges with insurance access, social support, transportation access, and overall health status that facilitate navigating the transplant steps. ³⁰⁻³³

Results from this study underscore the importance of pre-waitlisting data, including the collection of social risk factors, to elucidate factors influencing access to these key steps. Identifying the multi-level barriers to evaluation start and waitlisting for individuals with ESKD can help pinpoint individuals who may need targeted interventions to improve equity and access. Thus, our findings have important policy implications and highlight the significance of the forthcoming national data collection on pre-waitlisting steps.³⁴ Notably, pre-waitlisting data collection within the CMS-2728 form began in October 2024 and HRSA-directed national collection of pre-waitlisting data is anticipated to start soon;³⁵ ³⁴ however, several

years of follow-up and time to overcome data lags will be needed to fully assess regional differences using these data.³⁴ As these data emerge, transplant centers may face increased scrutiny to improve transplant access and equity therein. These data can be used to monitor upstream factors contributing to the observed variability in access to improve access to transplantation among all individuals with kidney failure.

Our findings must be interpreted in the context of their limitations. First, data are limited to centers voluntarily submitting to E-STAR, potentially excluding patients evaluated or waitlisted at non-E-STAR centers and affecting generalizability to other regions with distinct patient demographics and care practices. ¹⁶ However, the observed variation aligns with national studies of geographic variation in other transplant steps. ^{8,17,18,36} Second, value-based care models with geographically varying implementation were introduced during the study period, such as Kidney Care Choices and ESRD Treatment Choices, may have influenced access and disparities, warranting future investigation. Given overlap with the COVID-19 pandemic, disruptions in healthcare delivery likely influenced referral and evaluation behaviors. ³⁷ Additionally, the lack of a standardized definition of evaluation start could confound findings of variation in rates, as could differences in how centers define referral and close referrals. However, 94% of E-STAR centers define evaluation start as the patient's initial contact with the center. Patient-level data captured on the CMS-2728 Medical Evidence Form at dialysis start may be underreported or have changed between dialysis start and progression through referral, evaluation, and waitlisting. Lastly, there is potential for residual confounding by unmeasurable factors influencing patient eligibility and access in the current analysis due to the reliance on patient-level data captured within USRDS.

In summary, substantial variation in timely evaluation and waitlisting exists between individuals treated for kidney failure across four US regions, with barriers differing by step and region. These findings demonstrate how pre-waitlisting surveillance data can be used to better understand this variation and to promote equity in access to transplantation through interventions and policy changes, such as the new federal payment policy (IOTA) and implementation of the OPTN Modernization Act.

AUTHOR CONTRIBUTIONS 386 Ms. Buford, Ms. Di, and Dr. Patzer had full access to all of the data in the study and take responsibility 387 388 for the integrity of the data and the accuracy of the data analysis. Study concept and design: All authors 389 390 Acquisition, analysis, or interpretation of data: All authors Drafting of the manuscript: Buford, Patzer, Di, Harding 391 392 Critical revision of the manuscript for important intellectual content: All authors. 393 Statistical analysis: Buford, Di, Patzer Obtained funding: Patzer, Pastan. 394 Administrative, technical, or material support: Patzer, Buford, Di, Harding, Drewry, Wilk, Pastan 395 396 **DISCLOSURES** 397 None. 398 **FUNDING/SUPPORT** 399 This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases 400 (R01DK122701). 401 **ROLE OF FUNDER/SPONSOR:** The study funder/sponsor had no role in the design and conduct of the study; collection, management, 402 403 analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to 404 submit the manuscript for publication. 405 DATA SHARING STATEMENT The data reported here have been supplied in part by the USRDS. Deidentified data from the Early Steps 406 407 to Transplant Access Registry are available upon request and with a signed data use agreement with the Regenstrief Institute and Indiana University. 408 409

ACKNOWLEDGEMENTS

The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government. The authors acknowledge the Island Peer Review Organization (IPRO) for its role as the data coordinating center for E-STAR, Dr. Liise Kayler for her role as a member of our E-STAR community advisory board (also referred to as "Transplant Champion"), all transplant centers who voluntary submit data to E-STAR, and all members of the Southeastern Kidney Transplant Coalition for their significant assistance in conceptualizing and maintaining E-STAR.

421	SUPPLEMENTARY MATERIAL
422	eAppendix. Definition of Transplant Medical Evaluation Start.
423	eAppendix. Factors Associated With Patient Evaluation Start and Waitlisting
424	eTable 1. Overview of Data Availability for Each Outcome by De-Identified Transplant Center: Logistic
425	Regression Analysis
426	eTable 2. Overview of Data Availability for Each Outcome by De-Identified Transplant Center:
427	Multivariable-adjusted competing risk analysis
428	eTable 3. Overview of Evaluation Start Definition by De-Identified Transplant Center
429	eTable 4. Cumulative incidence of evaluation start within six months of referral among those referred for
430	a kidney transplantation and waitlisting within 1 year of evaluation start among those that started the
431	evaluation, accounting for the competing risk of death, displayed by end-stage renal disease network.
432	eTable 5. Competing risks modeling results for the association of ESRD Network with evaluation start
433	among those referred and waitlisting among those who started evaluation in ESRD Networks 1, 2, 6, and
434	9: 2015-2024.
435	eFigure 1. Cumulative incidence of evaluation start within six months of referral among those referred
436	for a kidney transplantation (dashed line), accounting for the competing risk of death (solid line),
437	displayed by end-stage renal disease network.
438	eFigure 2. Cumulative incidence of waitlisting within one year of evaluation start among those who
439	started the evaluation for a kidney transplantation (dashed line), accounting for the competing risk of
440	death (solid line), displayed by end-stage renal disease network.

- United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney
 disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive
 and Kidney Diseases, Bethesda, MD, 2022.
- Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. *Am J Transplant*. 2011;11(10):2093-2109. doi:10.1111/j.1600-6143.2011.03686.x
- 450 3. Axelrod DA, Schnitzler MA, Xiao H, et al. An economic assessment of contemporary kidney transplant practice. *Am J Transplant*. 2018;18(5):1168-1176. doi:10.1111/ajt.14702
- 452 4. Patzer RE, Paul S, Plantinga L, et al. A Randomized Trial to Reduce Disparities in Referral for 453 Transplant Evaluation. *J Am Soc Nephrol*. 2017;28(3):935-942. doi:10.1681/ASN.2016030320
- 5. Patzer RE, McPherson L, Wang Z, et al. Dialysis facility referral and start of evaluation for kidney transplantation among patients treated with dialysis in the Southeastern United States. *Am J Transplant*. 2020;20(8):2113-2125. doi:10.1111/ajt.15791
- Waterman AD, Rodrigue JR, Purnell TS, Ladin K, Boulware LE. Addressing racial and ethnic disparities in live donor kidney transplantation: priorities for research and intervention. *Semin Nephrol*. 2010;30(1):90-98. doi:10.1016/j.semnephrol.2009.10.010
- Waterman AD, Peipert JD, Hyland SS, McCabe MS, Schenk EA, Liu J. Modifiable patient
 characteristics and racial disparities in evaluation completion and living donor transplant. *Clin J Am Soc Nephrol*. 2013;8(6):995-1002. doi:10.2215/CJN.08880812
- 463 8. Ashby VB, Kalbfleisch JD, Wolfe RA, Lin MJ, Port FK, Leichtman AB. Geographic variability 464 in access to primary kidney transplantation in the United States, 1996-2005. *Am J Transplant*. 2007;7(5 Pt 465 2):1412-1423. doi:10.1111/j.1600-6143.2007.01785.x
- Patzer RE, Perryman JP, Schrager JD, et al. The role of race and poverty on steps to kidney
 transplantation in the Southeastern United States. *Am J Transplant*. 2012;12(2):358-368.
 doi:10.1111/j.1600-6143.2011.03927.x
- Patzer RE, Amaral S, Klein M, et al. Racial disparities in pediatric access to kidney
 transplantation: does socioeconomic status play a role?. *Am J Transplant*. 2012;12(2):369-378.
 doi:10.1111/j.1600-6143.2011.03888.x
- Patzer RE, Amaral S, Wasse H, Volkova N, Kleinbaum D, McClellan WM. Neighborhood
 poverty and racial disparities in kidney transplant waitlisting. *J Am Soc Nephrol*. 2009;20(6):1333-1340.
 doi:10.1681/ASN.2008030335
- Hall YN, Choi AI, Xu P, O'Hare AM, Chertow GM. Racial ethnic differences in rates and determinants of deceased donor kidney transplantation. *J Am Soc Nephrol*. 2011;22(4):743-751. doi:10.1681/ASN.2010080819
- Harding JL, Perez A, Snow K, et al. Non-medical barriers in access to early steps of kidney transplantation in the United States A scoping review. *Transplant Rev (Orlando)*. 2021;35(4):100654. doi:10.1016/j.trre.2021.100654
- Hat 14. Patzer RE, McClellan WM. Influence of race, ethnicity and socioeconomic status on kidney disease. *Nat Rev Nephrol*. 2012;8(9):533-541. doi:10.1038/nrneph.2012.117
- 483 15. Patzer RE, Pastan SO. Policies to promote timely referral for kidney transplantation. *Semin Dial*. 484 2020;33(1):58-67. doi:10.1111/sdi.12860
- 485 16. Patzer RE, Plantinga LC, Paul S, et al. Variation in Dialysis Facility Referral for Kidney
- Transplantation Among Patients With End-Stage Renal Disease in Georgia. *JAMA*. 2015;314(6):582-594. doi:10.1001/jama.2015.8897
- Davis AE, Mehrotra S, McElroy LM, et al. The extent and predictors of waiting time geographic disparity in kidney transplantation in the United States. *Transplantation*. 2014;97(10):1049-1057.
- 490 doi:10.1097/01.tp.0000438623.89310.dc
- 491 18. Zhou S, Massie AB, Luo X, et al. Geographic disparity in kidney transplantation under KAS. Am
- 492 *J Transplant*. 2018;18(6):1415-1423. doi:10.1111/ajt.14622

- 493 19. Patzer RE, Plantinga L, Krisher J, Pastan SO. Dialysis facility and network factors associated
- with low kidney transplantation rates among United States dialysis facilities. *Am J Transplant*.
- 495 2014;14(7):1562-1572. doi:10.1111/ajt.12749
- 496 20. P.L. 118-14
- 497 21. 89 FR 96280
- 498 22. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J
- 499 *Am Stat Assoc.* 1999/06/01 1999;94(446):496-509. doi:10.1080/01621459.1999.10474144
- 500 23. Syed ST, Gerber BS, Sharp LK. Traveling towards disease: transportation barriers to health care
- 501 access. J Community Health. 2013;38(5):976-993. doi:10.1007/s10900-013-9681-1
- 502 24. Probst JC, Laditka SB, Wang JY, Johnson AO. Effects of residence and race on burden of travel
- for care: cross sectional analysis of the 2001 US National Household Travel Survey. BMC Health Serv
- 504 Res. 2007;7:40. Published 2007 Mar 9. doi:10.1186/1472-6963-7-40
- 505 25. Browne T, McPherson L, Retzloff S, et al. Improving Access to Kidney Transplantation:
- Perspectives From Dialysis and Transplant Staff in the Southeastern United States. *Kidney Med.*
- 507 2021;3(5):799-807.e1. Published 2021 Jul 7. doi:10.1016/j.xkme.2021.04.017
- 508 26. Hamoda RE, McPherson LJ, Lipford K, et al. Association of sociocultural factors with initiation
- of the kidney transplant evaluation process. *Am J Transplant*. 2020;20(1):190-203. doi:10.1111/ajt.15526
- 510 27. Gillespie A, Hammer H, Lee J, Nnewihe C, Gordon J, Silva P. Lack of listing status awareness:
- results of a single-center survey of hemodialysis patients. Am J Transplant. 2011;11(7):1522-1526.
- 512 doi:10.1111/j.1600-6143.2011.03524.x
- 513 28. Urbanski M, Buford J, McDonnell J, Bowers M, Pastan S, Patzer RE. "Interviewing for Your
- Life": Exploring Patient Experiences Accessing Kidney Transplant in the U.S. In: American Transplant
- 515 *Congress (ATC)*. 2024:
- 516 29. Whelan AM, Johansen KL, Copeland T, et al. Kidney transplant candidacy evaluation and
- waitlisting practices in the United States and their association with access to transplantation. Am J
- 518 *Transplant*. 2022;22(6):1624-1636. doi:10.1111/ajt.17031
- 519 30. Berry J, Perez A, Di M, et al. The Association between Residential Segregation and Access to
- 520 Kidney Transplantation: Evidence from a Multistate Cohort Study. Clin J Am Soc Nephrol.
- 521 2024;19(11):1473-1484. doi:10.2215/CJN.0000000000000565
- 522 31. Clark CR, Hicks LS, Keogh JH, Epstein AM, Ayanian JZ. Promoting access to renal
- transplantation: the role of social support networks in completing pre-transplant evaluations. J Gen Intern
- 524 *Med.* 2008;23(8):1187-1193. doi:10.1007/s11606-008-0628-7
- 525 32. Hendryx MS, Ahern MM, Lovrich NP, McCurdy AH. Access to health care and community
- 526 social capital. *Health Serv Res.* 2002;37(1):87-103.
- 527 33. Wolfe MK, McDonald NC, Holmes GM. Transportation Barriers to Health Care in the United
- 528 States: Findings From the National Health Interview Survey, 1997-2017. *Am J Public Health*.
- 529 2020;110(6):815-822. doi:10.2105/AJPH.2020.305579
- 530 34. HRSA directive to expand OPTN data collection. Organ Procurement and Transplantation
- Network; 2024. 2/07/2024. https://optn.transplant.hrsa.gov/news/hrsa-directive-to-expand-optn-data-
- 532 collection/
- 533 35. End Stage Renal Disease Medical Evidence Report Medicare Entitlement and/or Patient
- 534 Registration (CMS-2728) (2023).
- 535 36. McPherson LJ, Di M, Adams AA, Plantinga L, Pastan SO, Patzer RE. Geographic Differences in
- Racial Disparities in Access to Kidney Transplantation. Kidney Int Rep. 2023;8(11):2474-2477. Published
- 537 2023 Aug 11. doi:10.1016/j.ekir.2023.08.002
- 538 37. Perez A, Retzloff S, Browne T, et al. Dialysis Staff-Reported Impact of COVID-19 on Early
- 539 Kidney Transplant Steps. *Kidney Int Rep.* 2022;7(4):904-907. doi:10.1016/j.ekir.2022.01.007

Table 1. Baseline Dialysis Facility- and Patient-Level Characteristics of Patients Referred for a Transplant: 2015-2023

		ESRD Network			
	Total Study Population (N=62,467)	New England N=8,797	New York N=9,893	Southeast N=30,874	Ohio River Valley N=12,903
Facility-Level Characteristics ^b					
No. of patients per facility, mean (SD) ^c Patient to social worker ratio, mean (SD) ^d	88.4 (56.9) 64.3 (33.3)	96.1 (56.2) 68.3 (34.1)	120.1 (74.1) 80.2 (40.1)	83.6 (50.8) 63.1 (31.5)	70.3 (44.4) 52.4 (27.8)
Freestanding facility, N (%) ^g	57,380 (91.9%)	7,592 (86.3%)	7,747 (78.3%)	29,939 (97.0%)	12,102 (93.8%)
Profit Status, n (%) ^h					
Non-profit	10,262 (16.4%)	1,465 (16.7%)	3,152 (31.9%)	4,126 (13.4%)	1,519 (11.8%)
For-profit	52,048 (83.3%)	7,261 (82.5%)	6,703 (67.8%)	26,722 (86.6%)	11,362 (88.1%)
Characteristics of Patients within	- , (,	(,	-,(,	-,- (,	, (,
Facility Mean age in years, mean (SD) Age category in years, N (%) ⁱ	52.7 (13.9%)	53.0 (14.2)	52.7 (0.5%)	52.8 (13.8)	52.3 (14.0)
18-30	4,434 (7.1%)	700 (8.0%)	707 (7.1%)	2,062 (6.7%)	965 (7.5%)
30-40	7,494 (12.0%)	986 (11.2%)	1,179 (11.9%)	3,703 (12.0%)	1,626 (12.6%)
40-50	11,805 (18.9%)	1,516 (17.2%)	1,839 (18.6%)	6,031 (19.5%)	2,419 (18.7%)
50-60	16,329 (26.1%)	2,299 (26.1%)	2,588 (26.2%)	8,071 (26.1%)	3,371 (26.1%)
60-70	15,847 (25.4%)	2,297 (26.1%)	2,525 (25.5%)	7,758 (25.1%)	3,267 (25.3%)
70-80	6,391 (10.2%)	977 (11.1%)	1,028 (10.4%)	3,155 (10.2%)	1,231 (9.5%)
Male sex, N (%)	38,088 (61.0%)	5,600 (63.7%)	6,263 (63.3%)	18,181 (58.9%)	8,044 (62.3%)
Race, N (%) ^j					
White, non-Hispanic	23,570 (37.7%)	4,605 (52.3%)	2,850 (28.8%)	8,935 (28.9%)	7,180 (55.6%)
Black	31,780 (50.9%)	2,414 (27.4%)	4,305 (43.5%)	20,043 (64.9%)	5,018 (38.9%)
White, Hispanic	4,039 (6.5%)	1,102 (12.5%)	1,537 (15.5%)	982 (3.2%)	418 (3.2%)
Other race/ethnicity Attributed cause of ESKD, N (%) ^k	2,659 (4.3%)	429 (4.9%)	1,156 (11.7%)	834 (2.7%)	240 (1.9%)
Diabetes	26,767 (42.8%)	3,813 (43.3%)	4,239 (42.8%)	12,890 (41.8%)	5,825 (45.1%)
Hypertension	19,528 (31.3%)	1,842 (20.9%)	2,751 (27.8%)	11,559 (37.4%)	3,376 (26.2%)
Glomerulonephritis	7,361 (11.8%)	1,432 (16.3%)	1,279 (12.9%)	2,997 (9.7%)	1,653 (12.8%)
Cystic Kidney	1,470 (2.4%)	325 (3.7%)	253 (2.6%)	525 (1.7%)	367 (2.8%)
Other	7,253 (11.6%)	1,368 (15.6%)	1,351 (13.7%)	2,865 (9.3%)	1,669 (12.9%)
Facility % of incident patient clinical and laboratory measures					
Comorbidities, N (%)					
Obese (BMI \geq 35 kg/m2)	15,893 (25.4%)	1,779 (20.2%)	1,993 (20.1%)	8,304 (26.9%)	3,817 (29.6%)
Congestive heart failure Atherosclerotic heart disease	14,453 (23.1%) 5,800 (9.3%)	2,136 (24.3%) 1,270 (14.4%)	2,178 (22.0%) 1,283 (13.0%)	7,044 (22.8%) 1,981 (6.4%)	3,095 (24.0%) 1,266 (9.8%)
Other cardiac disease	8,784 (14.1%)	1,403 (15.9%)	1,192 (12.0%)	4,069 (13.2%)	2,120 (16.4%)
Cerebrovascular disease (stroke)	4,299 (6.9%)	586 (6.7%)	637 (6.4%)	2,196 (7.1%)	880 (6.8%)
Peripheral vascular disease	4,300 (6.9%)	915 (10.4%)	670 (6.8%)	1,766 (5.7%)	949 (7.4%)
Hypertension	55,556 (88.9%)	7391 (84.0%)	8,789 (88.8%)	2,7978 (90.6%)	11,398 (88.3%)
Diabetes	34,156 (54.7%)	4,510 (51.3%)	5,177 (52.3%)	17,333 (56.1%)	7,136 (55.3%)
Chronic obstructive pulmonary disease	3,571 (5.7%)	554 (6.3%)	453 (4.6%)	1,571 (5.1%)	993 (7.7%)

Tobacco use	4,916 (7.9%)	625 (7.1%)	484 (4.9%)	2,513 (8.1%)	1,294 (10.0%)
Cancer	2,537 (4.1%)	452 (5.1%)	397 (4.0%)	1,085 (3.5%)	603 (4.7%)
Patient socioeconomic characteristics					
Pre-ESKD nephrology care, N (%)	40,362 (64.6%)	6,057 (68.9%)	5,805 (58.7%)	19,773 (64.0%)	8,727 (67.6%)
Patient has been informed of kidney transplant options, N (%) ¹	54,165 (86.7%)	6,835 (77.7%)	8,970 (90.7%)	26,996 (87.4%)	11,364 (88.1%)
Primary health insurance provider, N (%) ^m					
Medicaid	19,048 (30.5%)	3,578 (40.7%)	4,505 (45.5%)	6,814 (22.1%)	4,151 (32.2%)
Medicare	17,140 (27.4%)	2,098 (23.8%)	2,033 (20.5%)	9,417 (30.5%)	3,592 (27.8%)
Employer group	14,984 (24.0%)	1,961 (22.3%)	2,283 (23.1%)	7,236 (23.4%)	3,504 (27.2%)
Other coverage	4,788 (7.7%)	618 (7.0%)	710 (7.2%)	2,630 (8.5%)	830 (6.4%)
No coverage	6,001 (9.6%)	268 (3.0%)	312 (3.2%)	4,647 (15.1%)	774 (6.0%)
Patient neighborhood (ZIP code) characteristics					
Average % black, mean (SD) ^e	29.2 (25.9)	14.2 (18.2)	28.3 (27.7)	36.8 (24.2)	21.9 (26.3)
Average % high school graduates, mean (SD) ^f	85.5 (7.5)	87.0 (8.1)	83.3 (8.8)	85.1 (6.8)	87.4 (6.7)
Neighborhood poverty (% ZIP code residents below poverty), N (%) ^{g, h}					
<20% below poverty	38,678 (61.9%)	6,523 (74.2%)	6,336 (64.0%)	17,663 (57.2%)	8,156 (63.2%)
≥20% below poverty	23,162 (37.1%)	2,181 (24.8%)	3,521 (35.6%)	12,778 (41.4%)	4,682 (36.3%)

Abbreviations: SD, standard deviation; ESKD, end-stage kidney disease; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); COPD, Chronic obstructive pulmonary disease

iInfomation on patient age at kidney replacement therapy initiation missing for 167 patients (0.3%).

jRace and ethnicity information missing for 419 patients (0.7%).

IInformation on whether patient has been informed of kidney transplant options missing for 2460 patients (3.9%).

541

542

543

544

545

546

547

^a Data shown as the total number of patients (No.) and the percentage (%), unless indicated otherwise.

^bObtained from data from the CMS ESRD Annual Facility Survey and the CDC Dialysis Surveillance Survey within the USRDS facility dataset ^cInformation on number of patients within dialysis facility missing for 157 patients (0.3%).

^dNumber of patients for every 1 social worker. Information on dialysis facility patient-to-social worker ratio was missing for 735 patients (1.2%). Calculated only among those facilities that have social workers and whose information on the number of patients and social workers was not missing.

^{601 (1.0%)} missing average percent black.

^f601 (1.0%) missing average percentage of high school graduates.

g157 (0.3%) missing facility type.

^h157 (0.3%) missing facility profit status.

Patient attributable cause missing for 88 patients (0.1%).

^mInsurance information missing for 506 patients (0.8%).

ⁿObtained from American Community Survey Data, 2014-2018.

^oInformation on neighborhood poverty missing for 627 (1.0%).

Table 2. Characteristics of dialysis facilities with low, moderate, and high evaluation start for kidney transplantation within 6 months of referral: 2015-2023

		Tertile of Transplant Evaluation Start, Median (Range)				
Characteristic	Overall	Lowest 25.00 (0-39.13)	Middle 50.00 (39.29-58.18)	Highest 71.10 (58.33-100)	P-value ^a	
Facilities, No.	2471	822	819	830		
Total No. of patients	62467	16945	26389	19133		
Facility-Level Characteristics						
No. of patients per facility, mean (95% CI)	56.11 (54.28-57.95)	46.88 (44.2-49.55)	62.89 (59.91-65.86)	58.49 (54.79-62.2)	<.001	
Patient to social worker ratio, mean (95% CI)	48.78 (47.51-50.05)	41.31 (39.45-43.16)	52.52 (50.47-54.57)	52.4 (49.84-54.96)	<.001	
Freestanding facility, N (%)	2081 (86.06)	708 (88.39)	723 (89.37)	650 (80.45)	<.001	
Profit Status, N (%) Non-profit	507 (20.97)	141 (17.6)	152 (18.79)	214 (26.49)	<.001	
For-profit	1911 (79.03)	660 (82.4)	657 (81.21)	594 (73.51)		
Facility Incident Patient-Level	(,	,	,	(, , , ,		
Characteristics						
Age category in years, mean % (95% CI)						
18-30	10.12 (9.37-10.86)	9.18 (7.86-10.5)	8.47 (7.54-9.39)	12.67 (11.13-14.21)	<.001	
30-40	13.27 (12.63-13.9)	13.4 (12.18-14.61)	12.11 (11.35-12.88)	14.27 (13.01-15.53)	0.02	
40-50	18.35 (17.69-19.02)	18.83 (17.48-20.18)	17.96 (17.13-18.79)	18.27 (17.06-19.47)	0.57	
50-60	24.52 (23.81-25.22)	24.2 (22.89-25.51)	25.46 (24.55-26.38)	23.89 (22.51-25.27)	0.17	
60-70	23.93 (23.21-24.65)	23.78 (22.4-25.16)	25.74 (24.75-26.73)	22.3 (20.98-23.62)	0.001	
70-80	9.82 (9.33-10.31)	10.61 (9.66-11.57)	10.26 (9.57-10.95)	8.59 (7.72-9.46)	0.002	
Male sex, mean % (95% CI) Race, mean % (95% CI)	62 (61.17-62.82)	61.66 (60.07-63.25)	61.67 (60.59-62.74)	62.66 (61.09-64.23)	0.53	
White, non-Hispanic	45.81 (44.51-47.1)	53.04 (50.71-55.37)	43.87 (41.86-45.88)	40.65 (38.36-42.93)	<.001	
Black	44.36 (43.08-45.63)	40.04 (37.74-42.34)	47.96 (45.89-50.02)	45.01 (42.79-47.24)	<.001	
Hispanic White	6.06 (5.57-6.55)	4.38 (3.63-5.14)	4.67 (4.04-5.29)	9.08 (8.01-10.15)	<.001	
Other	3.78 (3.39-4.16)	2.54 (1.93-3.14)	3.51 (2.97-4.05)	5.26 (4.45-6.07)	<.001	
Attributed cause of ESKD, mean % (95% CI)						
Diabetes	40.16 (39.27-41.04)	41.98 (40.3-43.67)	42.15 (40.97-43.33)	36.38 (34.75-38.02)	<.001	
Hypertension	29.23 (28.35-30.11)	28.89 (27.28-30.51)	30.27 (29.03-31.51)	28.54 (26.84-30.24)	0.25	
Glomerulonephritis	13.75 (13.04-14.47)	12.6 (11.34-13.86)	12.25 (11.36-13.14)	16.37 (14.91-17.84)	<.001	
Cystic Kidney	2.82 (2.5-3.13)	2.9 (2.23-3.56)	2.58 (2.2-2.95)	2.98 (2.43-3.52)	0.56	
Other	14.04 (13.35-14.73)	13.62 (12.34-14.91)	12.75 (11.88-13.63)	15.73 (14.38-17.08)	0.002	
Facility % of incident patient clinical and laboratory measures						
Comorbidities, mean % (95% CI)	0.5 0.5 (0.5 0.5 5.5 5.5	20 4 (27 22 22 22	0.5 15 (0.5 -5 -5 -)	22.04.426.77.77	001	
Obese (BMI \geq 35 kg/m2)	25.95 (25.2-26.7)	29.4 (27.89-30.9)	26.47 (25.52-27.41)	22.06 (20.72-23.4)	<.001	
Congestive heart failure	22.29 (21.56-23.03)	24.47 (23.01-25.93)	22.57 (21.54-23.59)	19.89 (18.59-21.18)	<.001	
Atherosclerotic heart disease	9.75 (9.15-10.34)	10.41 (9.29-11.53)	9.18 (8.37-10)	9.67 (8.54-10.79)	0.25	
Other cardiac disease	15.04 (14.38-15.7)	16.75 (15.44-18.06)	15.1 (14.22-15.99)	13.3 (12.1-14.49)	<.001	
Cerebrovascular disease (stroke)	6.74 (6.33-7.16)	7.48 (6.6-8.36)	7.08 (6.53-7.64)	5.69 (4.99-6.39)	0.001	
Peripheral vascular disease	7.1 (6.61-7.59)	8.28 (7.26-9.29)	6.96 (6.29-7.63)	6.09 (5.28-6.9)	0.002	
Hypertension	89.43 (88.88-89.97)	89.41 (88.36-90.47)	89.89 (89.15-90.64)	88.97 (87.96-89.99)	0.40	
Diabetes	53.36 (52.46-54.26)	55.46 (53.74-57.18)	54.46 (53.25-55.67)	50.21 (48.55-51.88)	<.001	

Chronic obstructive pulmonary	6.23 (5.81-6.64)	7.99 (7.18-8.81)	6.15 (5.58-6.71)	4.58 (3.86-5.29)	<.001
disease					<.001
Tobacco use	8.13 (7.63-8.62)	9.87 (8.86-10.87)	9.17 (8.4-9.93)	5.39 (4.63-6.14)	<.001
Cancer	4.4 (4.04-4.77)	4.84 (4.14-5.54)	3.98 (3.57-4.39)	4.39 (3.66-5.12)	0.1688
Patient socioeconomic	90.3 (89.61-90.98)	88.81 (87.45-90.17)	88.8 (87.63-89.96)	93.26 (92.29-94.22)	<.001
characteristics					<.001
Patient has been informed of kidney					
transplant options, mean % (95% CI)					
Pre-ESKD nephrology care, mean %					0.08
(95% CI)	90.3 (89.61-90.98)	88.81 (87.45-90.17)	88.8 (87.63-89.96)	93.26 (92.29-94.22)	0.08
No					0.49
Yes	16.94 (16.29-17.6)	16.06 (14.82-17.3)	17.89 (16.9-18.88)	16.88 (15.71-18.05)	0.12
Unknown	65.18 (64.19-66.17)	65.63 (63.78-67.47)	65.59 (64.16-67.03)	64.33 (62.51-66.16)	
Primary health insurance provider,					0.42
mean % (95% CI)	17.88 (16.95-18.8)	18.31 (16.56-20.06)	16.52 (15.19-17.84)	18.79 (17.07-20.5)	0.42
Medicaid					0.006
Medicare	29.4 (28.52-30.29)	29.81 (28.21-31.42)	28.56 (27.34-29.78)	29.84 (28.11-31.56)	<.001
Employer group	29.9 (29.07-30.73)	31.81 (30.24-33.37)	29.23 (28.16-30.3)	28.7 (27.07-30.34)	0.45
Other coverage	24.53 (23.76-25.31)	22.1 (20.68-23.52)	24.74 (23.64-25.84)	26.7 (25.22-28.18)	<.001
No coverage	7.94 (7.43-8.45)	7.47 (6.6-8.35)	8.14 (7.35-8.94)	8.2 (7.23-9.17)	<.001
Patient neighborhood (ZIP code)					
characteristics					
Average % black, mean (95% CI)	24.29 (23.52-25.05)	20.99 (19.7-22.27)	25.92 (24.64-27.21)	25.94 (24.56-27.32)	<.001
Average % high school graduates,	86.1 (85.9-86.29)	86.15 (85.84-86.46)	86.05 (85.73-86.38)	86.08 (85.72-86.44)	0.02
mean (95% CI)					0.92
Neighborhood poverty (% ZIP code	24.29 (23.52-25.05)	20.99 (19.7-22.27)	25.92 (24.64-27.21)	25.94 (24.56-27.32)	
residents below poverty), mean %					
(95% CI)					
<20% below poverty	65.72 (64.53-66.91)	63.16 (60.94-65.38)	63.1 (61.15-65.06)	70.84 (68.9-72.78)	<.001
≥20% below poverty	34.28 (33.09-35.47)	36.84 (34.62-39.06)	36.9 (34.94-38.85)	29.16 (27.22-31.1)	<.001

Abbreviations: CI, confidence interval; ESKD, end-stage kidney disease; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); COPD, Chronic obstructive pulmonary disease.

^aStatistical significance indicated in bold. The P value is <0.05

Table 3. Characteristics of dialysis facilities with low, moderate, and high waitlisting within one year of evaluation start: 2015-2024


	Tertile of Transplant Evaluation Start, Median (Range)				
Characteristic	Overall	Lowest 20 (0-32.5)	Middle 41.67 (32.56-50)	Highest 75 (50.55-100)	P-value ^a
Facilities, No. Total No. of patients	2290 32174	763 10956	789 14239	738 6979	
Facility-Level Characteristics	32171	10,50	11237	0,1,7	
No. of patients per facility, mean					004
(95% CI)	58.43 (56.53-60.34)	57.42 (54.71-60.13)	69.26 (65.81-72.72)	47.45 (43.94-50.97)	<.001
Patient to social worker ratio, mean					<.001
(95% CI)	50.48 (49.16-51.79)	49.2 (47.13-51.28)	55.17 (52.97-57.36)	46.26 (43.71-48.82)	
Freestanding facility, N (%)	1945 (86.44)	710 (93.79)	722 (91.74)	513 (72.66)	<.001
Profit Status, N (%) Non-profit	464 (20.62)	96 (12.68)	120 (15.25)	248 (35.13)	<.001
For-profit	1786 (79.38)	661 (87.32)	667 (84.75)	458 (64.87)	<.001
Facility Incident Patient-Level	1700 (77.00)	001 (07.02)	007 (01172)	.50 (0.107)	
Characteristics					
Age category in years, mean % (95% CI)					
18-30	10.79 (9.96-11.62)	6.08 (5.12-7.03)	7.42 (6.65-8.19)	19.26 (17.14-21.38)	<.001
30-40	14.25 (13.46-15.04)	10.61 (9.5-11.71)	13.71 (12.71-14.71)	18.6 (16.77-20.43)	<.001
40-50	18.42 (17.65-19.19)	17.4 (16.06-18.74)	18.92 (17.97-19.88)	18.95 (17.29-20.61)	0.18
50-60	25.15 (24.26-26.04)	27.67 (26.07-29.28)	26.4 (25.26-27.54)	21.21 (19.39-23.03)	<.001
60-70	24.23 (23.35-25.11)	28.51 (26.91-30.12)	26.02 (24.82-27.22)	17.89 (16.24-19.55)	<.001
70-80 Mala and manage 9/ (059/ CD)	7.16 (6.62-7.69)	9.73 (8.52-10.95)	7.53 (6.83-8.23)	4.09 (3.34-4.84)	<.001
Male sex, mean % (95% CI) Race, mean % (95% CI)	63.39 (62.38-64.4)	60.53 (58.76-62.3)	63.03 (61.79-64.28)	66.73 (64.57-68.9)	<.001
White, non-Hispanic	44.56 (43.14-45.99)	38.06 (35.67-40.45)	45.93 (43.72-48.13)	49.85 (47.11-52.6)	<.001
Black	44.64 (43.23-46.05)	53.01 (50.53-55.49)	44.07 (41.88-46.26)	36.56 (34.05-39.08)	<.001
Hispanic White	6.78 (6.16-7.4)	5.78 (4.7-6.86)	6.12 (5.37-6.88)	8.52 (7.18-9.86)	0.001
Other	4.02 (3.58-4.46)	3.15 (2.47-3.83)	3.88 (3.3-4.47)	5.06 (4.07-6.05)	0.002
Attributed cause of ESKD, mean % (95% CI)	4.02 (3.38-4.40)	3.13 (2.47-3.63)	3.00 (3.3-4.47)	3.00 (4.07-0.03)	0.002
Diabetes	39 (37.97-40.04)	42.74 (40.92-44.57)	41.85 (40.51-43.19)	32.1 (30.02-34.18)	<.001
Hypertension	29.06 (28.02-30.11)	34.23 (32.31-36.15)	29.38 (27.96-30.81)	23.39 (21.4-25.38)	<.001
Glomerulonephritis	14.87 (14.04-15.69)	9.21 (8.14-10.28)	13.08 (12.13-14.04)	22.61 (20.68-24.54)	<.001
Cystic Kidney	2.95 (2.58-3.32)	2.26 (1.7-2.83)	2.89 (2.42-3.37)	3.72 (2.89-4.56)	0.01
Other	14.11 (13.32-14.91)	11.56 (10.3-12.82)	12.79 (11.86-13.71)	18.18 (16.34-20.01)	<.001
Facility % of incident patient clinical and laboratory measures					
Comorbidities, mean % (95% CI)					
Obese (BMI \geq 35 kg/m ²)	23.5 (22.61-24.38)	26.91 (25.24-28.57)	24.51 (23.36-25.66)	18.87 (17.14-20.6)	<.001
Congestive heart failure	19.89 (19.06-20.73)	23.37 (21.77-24.98)	20.53 (19.45-21.61)	15.58 (13.99-17.17)	<.001
Atherosclerotic heart disease	8.73 (8.08-9.39)	8.74 (7.51-9.96)	8.72 (7.83-9.6)	8.75 (7.47-10.04)	1.00
Other cardiac disease	13.81 (13.06-14.55)	14.42 (13.04-15.79)	13.99 (12.92-15.06)	12.97 (11.52-14.42)	0.29
Cerebrovascular disease (stroke)	5.46 (5.04-5.89)	6.64 (5.81-7.46)	5.84 (5.26-6.43)	3.83 (3.04-4.62)	<.001
Peripheral vascular disease	6.27 (5.73-6.81)	6.63 (5.55-7.71)	6.33 (5.61-7.05)	5.84 (4.84-6.83)	0.50
Hypertension	89.28 (88.62-89.95)	90.23 (89.14-91.31)	89.17 (88.26-90.09)	88.42 (86.97-89.87)	0.10
Diabetes	52.15 (51.08-53.21)	58.31 (56.5-60.11)	53.81 (52.47-55.16)	43.94 (41.75-46.14)	<.001

Tobacco use 4.65 (4.2-5.1) 5.74 (4.84-6.64) 4.98 (4.33-5.63) 3.16 (2.39-3.94) 5.06 (4.15-5.97) < 3.00 (4.15-5.97)	001 001 57 001
Cancer 4.12 (3.68-4.55) 4.45 (3.62-5.28) 3.92 (3.38-4.47) 3.99 (3.12-4.85) 0.	57
Patient socioeconomic)01
	01
characteristics)01
Patient has been informed of kidney	<i>1</i> 01
transplant options, mean % (95% CI) 91.06 (90.32-91.8) 89.27 (87.81-90.72) 91.3 (90.24-92.36) 92.71 (91.41-94.02)	
Pre-ESKD nephrology care, mean %	
(95% CI)	
No 17.79 (16.96-18.61) 20.13 (18.53-21.73) 18.71 (17.6-19.82) 14.37 (12.84-15.91) <	001
Yes 66.43 (65.3-67.55) 62.85 (60.75-64.96) 67.53 (65.99-69.07) 68.94 (66.79-71.09) <	001
Unknown 15.79 (14.82-16.75) 17.02 (15.19-18.84) 13.76 (12.47-15.05) 16.68 (14.81-18.56) 0.	01
Primary health insurance provider,	
mean % (95% CI)	
Medicaid 27.77 (26.74-28.8) 28.23 (26.39-30.08) 27.74 (26.33-29.14) 27.32 (25.23-29.41) 0.	78
	001
Employer group 28 (27.01-28.99) 22.33 (20.82-23.84) 28.36 (27.1-29.62) 33.49 (31.28-35.69) <	001
Other coverage 8.02 (7.43-8.62) 7.62 (6.73-8.51) 8.8 (7.9-9.69) 7.61 (6.32-8.9) 0.	18
No coverage 8.4 (7.81-8.98) 11.45 (10.24-12.65) 8.3 (7.49-9.11) 5.34 (4.4-6.28) <	001
Patient neighborhood (ZIP code)	
characteristics	
	001
Average % high school graduates,	001
mean (95% CI) 86.08 (85.87-86.29) 85.26 (84.92-85.61) 86.32 (86-86.65) 86.66 (86.24-87.08)	701
Neighborhood poverty (% ZIP code	
residents below poverty), mean %	
(95% CI)	
	001
≥20% below poverty 33.91 (32.6-35.22) 40.57 (38.2-42.94) 33.27 (31.29-35.25) 27.7 (25.32-30.07) <	001

Abbreviations: CI, confidence interval; ESKD, end-stage kidney disease; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); COPD, Chronic obstructive pulmonary disease.

^aStatistical significance indicated in bold. The P value is <0.05

Figure 1. Flow diagram of study inclusion and exclusion criteria for study population (2015–2023).



582 583

584

585

586

587

588

578

579

^aEach bar represents an individual dialysis facility. Dialysis facilities are ordered sequentially based on the percentage of patients with each outcome. Each figure additionally displays the median (dotted line) and interquartile range (Q1-Q3) for the outcomes within each region.

^bSmall dialysis facilities (# of dialysis patients <20) were excluded.

^cThe denominator for calculating each outcome differed depending on data availability from each transplant center. See table S1 for a detailed description of data availability for each participating center.

